[{"content":"Chung M, Shelley JP, Karakoc G, et al. Arthritis Care \u0026amp; Research. 2026;78(5):662–669.\nTL;DR: In a 28,781-patient EMR phenome-wide study, a high ANA titer (≥1:640) without autoimmune disease was strongly enriched for non-AI liver disease (NAFLD/NASH, alcohol-related) and metabolic comorbidity — broadening the differential for an unexplained high-titer ANA beyond the usual autoimmune workup.\nThe Clinical Problem The antinuclear antibody (ANA) is one of the most frequently ordered rheumatologic tests, yet its interpretation outside the autoimmune (AI) context remains a perennial source of clinical anxiety. While a positive ANA is near-mandatory for SLE (\u0026gt;95% positivity) and is integral to the 2019 EULAR/ACR criteria (which require a titer ≥1:80), high titer ANAs (≥1:640) are found in approximately 2% of the general population — many of whom never develop a classifiable autoimmune disease.\nSeveral questions plague the bedside rheumatologist:\nDoes a high ANA titer in a non-AI patient indicate occult immune dysregulation? Should such patients be followed indefinitely, reassured, or worked up further? Earlier follow-up studies have shown that even at 10 years, only ~6% (2/34) of high-titer ANA individuals without AI disease at baseline went on to develop one — meaning the majority of high titers remain \u0026ldquo;unexplained.\u0026rdquo; Prior literature has linked positive ANAs to cardiovascular events, cancer, infections, and all-cause mortality, but results have been inconsistent. The clinical meaning of a high titer (not just any positive) in a non-autoimmune individual has remained essentially uncharted territory.\nThe Research Question Do individuals without autoimmune disease who carry a high ANA titer (≥1:640) show a measurably different burden of clinical diagnoses compared to those with low-titer or negative ANA results?\nThe authors hypothesized that high titers might reflect immune dysregulation that manifests phenotypically as increased risk for specific (non-AI) conditions — and used a phenome-wide association study (PheWAS) approach to let the data speak without an a priori bias toward any organ system.\nHow the Study Was Designed Setting \u0026amp; Design: Retrospective case-control study using Vanderbilt University Medical Center\u0026rsquo;s (VUMC) de-identified EMR system (Synthetic Derivative/BioVU).\nEligibility:\nAdults (≥18 years) with at least one clinician-ordered ANA test between January 2000 and October 2022. ANA performed exclusively by indirect immunofluorescence on HEp-2 cells (per ACR Task Force protocols), using Immuno Concepts or Inova Diagnostics assays. Highest titer was selected if multiple ANAs existed. Exclusion: any documented ANA-related AI disorder (SLE, Sjögren, SSc, MCTD, AI hepatitis, PBC, idiopathic inflammatory myopathies, etc.) — at any time point in the EMR, not just before testing. Group Allocation: Three mutually exclusive cohorts —\nHigh titer (HT): ANA ≥ 1:640 Low titer (LT): ANA ≤ 1:80 Negative (NG): Only negative ANA results Intermediate titers (1:80 \u0026lt; titer \u0026lt; 1:640) were deliberately excluded to sharpen the contrast. Phenotyping Approach (the technical heart of the study):\nICD-9 and ICD-10 codes were mapped to Phecodes (v1.2) — these aggregate related ICD codes into clinically meaningful disease entities. Cases = ≥2 occurrences of a Phecode in the EMR; Controls = absence of that Phecode or any closely related Phecode. Only diagnoses first recorded within ±90 days of the ANA test were counted — a clever design choice meant to reduce contamination by long-standing prevalent disease. Phecodes with \u0026lt;100 cases were dropped to preserve statistical power. Adjustments: age at ANA testing, sex, median BMI (15–60 kg/m² range), and reported race. Significance threshold: P \u0026lt; 5 × 10⁻⁵ (a Bonferroni-style correction for the large number of Phecodes tested). Case Validation: For the 10 most significant associations, 50 random charts were manually reviewed to compute the positive predictive value (PPV) of the Phecode-based phenotype.\nThe Study Population From an initial pool of 88,501 individuals with ANA tests:\n45,624 were excluded for established AI disease 4,700 lacked BMI data 8,488 had intermediate titers (excluded by design) 908 had no diagnostic code within ±90 days Final cohort: 28,781 individuals\nGroup n % Median Age (IQR) Negative (NG) 24,354 84.6% 45 (33–56) Low titer (LT) 3,544 12.3% 48 (37–60) High titer (HT) 883 3.1% 55 (42–66) Key observations on baseline characteristics:\nHT patients were significantly older (P = 3.9 × 10⁻⁷³), consistent with the known age-related rise in ANA prevalence. Female predominance across all groups (65–73%). BMI did not differ between groups (P = 0.345) — an important null finding that becomes interesting later. ANA patterns (available in 95.8% of HT vs only 23.4% of LT): Homogeneous (~57%) and Speckled (~38%) dominated. Nucleolar was ~3–5%. No striking pattern enrichment differentiated HT from LT. The Results Comparison 1 — HT vs LT (46 significant Phecode associations):\nThe top hits were overwhelmingly hepatic and metabolic:\nChronic liver disease (Phecode 571) NAFLD / NASH (Phecode 571.5) Alcohol-related liver disease (Phecode 317) Cirrhosis (non-alcoholic), alcoholic liver damage, portal hypertension, ascites, esophageal varices/bleeding, liver abscess Surrogates of severe liver disease: coagulation defects, thrombocytopenia, hyponatremia, acidosis, protein-calorie malnutrition, hepatic encephalopathy markers (altered mental status) Metabolic correlates: obesity, overweight, diabetes mellitus Behavioral/psychiatric: alcoholism, tobacco use disorder, anxiety, mood disorders An interesting finding: Pain (Phecode 338) was more common in HT (OR 4.1, P = 1.9 × 10⁻¹³), but myalgia (Phecode 770) was less common (OR 0.27, P = 1.3 × 10⁻⁵) — a likely reflection of referral and screening bias (myalgic patients with high ANA tend to get an AI label and would have been excluded). Comparison 2 — HT vs NG (67 significant associations):\n59 of the 67 overlapped with the HT vs LT findings. New associations: biliary tract disorders (cholelithiasis, cholecystitis), GI disorders (hemorrhoids, esophageal disease), bariatric surgery, insulin pump use, screening for skin malignancy, and poisoning by antibiotics, anti-infectives, and analgesics/antipyretics/antirheumatics (likely reflecting hepatotoxicity events in patients with underlying liver disease). Case Validation (the credibility check):\nFor Phecode 573 (\u0026ldquo;Other disorders of the liver\u0026rdquo;): PPV = 88% for non-AI liver disease. Fatty liver disease was the most common etiology, followed by alcohol and hepatitis C. Only 3/50 charts had possible undiagnosed AI liver disease (PBC or AIH) — i.e., the signal is not explained by missed autoimmune hepatitis. For alcohol-related Phecodes (317.1, 317.11): PPV = 92% for genuine alcohol-attributable disease. Sensitivity analyses:\nExcluding BMI as a covariate did not alter the conclusions. Among HT individuals, ANA patterns did not differ between those with and without liver disease — so no single immunofluorescent pattern is acting as a \u0026ldquo;tag\u0026rdquo; for hepatic disease. Study Limitations The authors are commendably forthcoming. The key caveats:\nPhenotype misclassification — Phecodes derived from ICD codes can over- or under-call diagnoses; mitigated (but not eliminated) by the 88–92% PPVs. Future AI disease — some HT individuals may develop AI disease later; excluding ever-diagnosed AI patients reduces but does not eliminate this. Incident vs prevalent disease — the ±90 day window helps, but patients newly enrolled at VUMC may have brought chronic diagnoses with them. Single-center, tertiary referral cohort — generalizability to community settings is uncertain. Pre-ICAP era testing — most ANAs predate the International Consensus on ANA Patterns (ICAP, 2019) recommendations, so pattern reporting was less standardized. DFS70 not assessed — these antibodies (dense fine speckled pattern) are notoriously difficult to detect by HEp-2 IIF alone and require solid-phase confirmation. They are associated with the absence of systemic AI disease, and whether DFS70 positivity drives some of the signal here remains unknown. Causality cannot be inferred — does the high ANA reflect underlying liver disease, or does the immune dysregulation drive both? PheWAS cannot disentangle this. How This Study Adds to Practice This is the first large-scale, hypothesis-free evaluation of what a high ANA titer means in patients without autoimmune disease. The clinical implications:\nNon-autoimmune liver disease deserves a formal place in the differential of an unexplained high-titer ANA. Currently, most algorithms emphasize AI hepatitis or PBC; this study shows NAFLD/NASH and alcoholic liver disease are quantitatively more important explanations. The mechanism likely involves oxidative stress — chronic alcohol, tobacco, and lipotoxicity all generate reactive species and neoantigens (e.g., malondialdehyde-acetaldehyde adducts) that can drive autoantibody production without triggering full-blown AI disease. The signal extends beyond liver involvement itself to its complications — cirrhosis, portal hypertension, varices, ascites, coagulopathy. This raises the question of whether high ANA titers might be a marker of progression in NAFLD, although the cross-sectional design cannot confirm this. Metabolic comorbidity matters — despite similar median BMI across groups, the distribution skewed toward obesity in HT patients (twice the proportion in overweight/obese categories), and bariatric surgery and insulin pump use were enriched. The \u0026ldquo;inverse BMI-ANA association\u0026rdquo; seen in some prior epidemiologic studies may be confounded by NAFLD-driven cases. For the rheumatologist: when you encounter a referral for a \u0026ldquo;high ANA without symptoms,\u0026rdquo; consider checking LFTs, asking about alcohol use, and screening for metabolic syndrome / NAFLD risk factors before committing to indefinite serial autoimmune workups. Final Takeaways A high ANA titer (≥1:640) in a person without autoimmune disease is not biologically silent — it is statistically enriched for liver disease (NAFLD/NASH, ALD) and its sequelae. The Phecode-based PheWAS approach offers a powerful, hypothesis-free way to interrogate large EMR datasets, and the manual chart validation (PPV 88–92%) lends credibility to the top associations. The mechanistic thread is plausibly oxidative stress → autoantibody generation in the setting of chronic hepatic and metabolic injury. Rheumatologists should broaden the differential for an unexplained high-titer ANA to include hepatic and metabolic disorders. Reflexively repeating ANAs or pursuing exhaustive AI workups in such patients may be lower-yield than a focused hepatology evaluation. Open questions for the field: Does the high ANA predict progression of NAFLD to fibrosis? What is the role of DFS70 in this population? Is there value in serial ANA monitoring in liver disease patients? Can the immunologic phenotype of these patients be reversed by treating the metabolic/hepatic driver? A useful one-liner for clinic: An ANA of 1:640 in a healthy-looking patient may be a quiet flag for an unhealthy liver — check the LFTs before you check the dsDNA.\nOriginal article Chung M, Shelley JP, Karakoc G, et al.. Clinical Conditions Associated With a High ANA Titer in Individuals Without Autoimmune Disease. Arthritis Care \u0026amp; Research (2026).\ndoi:10.1002/acr.25682 ","permalink":"https://rheumatologydigest.org/posts/high-ana-titer-non-autoimmune/","summary":"In a 28,781-patient EMR phenome-wide study, a high ANA titer (≥1:640) without autoimmune disease was strongly enriched for non-AI liver disease (NAFLD/NASH, alcohol-related) and metabolic comorbidity — broadening the differential for an unexplained high-titer ANA beyond the usual autoimmune workup.","title":"Clinical conditions associated with a high ANA titer in non-autoimmune individuals"},{"content":"A detailed summary of the Current Opinion review by Koumpouras \u0026amp; Caricchio (Curr Opin Rheumatol 2026; 38:155–162)\nTL;DR: CD19 CAR-T cellular therapy delivers drug-free remission in 80–85% of refractory SLE patients in early-phase trials, with similar signals in IIM and SSc — the first credible attempt at true immunological reset, replacing chronic immunosuppression with a one-and-done intervention.\nThe Clinical Problem Despite a steady expansion of the therapeutic armamentarium, systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc) still leave a substantial proportion of patients with refractory disease, accumulating organ damage, and steroid-related comorbidity.\nKey limitations of current paradigms:\nConventional immunosuppressants and even newer targeted agents (type I IFN receptor blockade with anifrolumab, BAFF inhibition with belimumab, calcineurin inhibition with voclosporin) improve outcomes but rarely deliver durable, complete renal remission. Cumulative glucocorticoid exposure continues to drive damage and comorbidity. Attempts to taper immunosuppression in proliferative lupus nephritis are typically thwarted by relapse — reflecting the failure of conventional therapy to truly reset autoimmunity. Anti-CD20 antibody-based depletion is incomplete: Phase II/III rituximab trials in SLE missed their primary endpoints; even type II anti-CD20 obinutuzumab (REGENCY trial) gives deeper depletion and better renal responses but seldom produces sustained drug-free remission. A paradoxical \u0026ldquo;unmet need amidst an overcrowded pipeline\u0026rdquo; is now evident — more than 30 active interventional trials are exploring cell-based strategies in lupus nephritis alone (149 trials worldwide in LN, 34 of which are CAR-T trials, per ClinicalTrials.gov, Oct 2025).\nWhat the Paper Explains This is a narrative review synthesising the rationale, current clinical experience, safety landscape, and emerging platforms for cellular therapy in rheumatic disease. The authors cover six conceptual areas, summarised below.\n1. Foundations of Cellular Immunotherapy \u0026amp; CAR Design The field grew out of oncology — IL-2-expanded lymphocytes, tumour-infiltrating lymphocytes, then retroviral gene transfer of tumour-reactive receptors into autologous T cells. A chimeric antigen receptor (CAR) combines: An extracellular single-chain variable fragment (scFv) for antigen recognition Intracellular CD3ζ activation domain One or more co-stimulatory domains — typically CD28 or 4-1BB Design matters: CD28-based CARs → brisk expansion, shorter persistence 4-1BB-based CARs → slower expansion, longer persistence Most autoimmune programmes have therefore converged on CD19–4-1BB architectures, to balance deep B-cell depletion with manageable toxicity. 2. Why CD19 Is a Compelling Target in Autoimmunity CD19 spans a broader B-lineage range than CD20 — from pro-B cells through naïve and memory B cells, plasmablasts, and a subset of short-lived plasma cells. CD20 is absent from pro-B cells and many antibody-secreting cells. CD19-directed CAR-T can therefore reach autoreactive cells in tissue niches or microenvironments that monoclonal antibodies struggle to penetrate. Important nuance: In murine SLE models, CD19 CAR-T prolongs survival and prevents glomerulonephritis when depletion is sustained. However, in the Fra2 TG murine model of SSc, deep B-cell depletion did NOT help — it exacerbated disease (Avouac et al., A\u0026amp;R 2024). This is a not-so-obvious cautionary signal that mechanisms beyond simple B-cell depletion may be relevant in SSc. Practical feasibility: Leukapheresis and CAR-T manufacturing have proven feasible even in patients on background immunosuppression; ex vivo cytotoxicity of SLE-derived CAR-T products is comparable to that of healthy-donor products. 3. Clinical Experience in SLE, IIM, and SSc Sequential milestones:\nFirst case (Mackensen 2022): A young adult with refractory SLE + active lupus nephritis received CD19–4-1BB CAR-T → rapid B-cell depletion → complete clinical and serological remission, drug-free. Five-patient series: All achieved DORIS-defined drug-free remission within 3 months, normal complement, minimal/no proteinuria, and B-cell repopulation predominantly with naïve cells — a key feature of \u0026ldquo;immune reset.\u0026rdquo; Erlangen Phase I/II basket study (n = 24): 17 women, 7 men; median age 39 years 10 SLE, 9 SSc, 5 IIM Median of 4 prior immunosuppressive treatments CRS: 18/24 developed CRS — 17 grade 1, 1 grade 2; no higher-grade CRS, no ICANS No clinically relevant cytopenia \u0026gt;4 weeks One grade 3 event — renal thrombotic microangiopathy with CMV co-infection LICATS in 88% (mostly grade 1/2) B-cell depletion in all patients 6-month efficacy (19/24 patients): 7/7 SLE → DORIS remission 8/8 SSc → no disease progression 4/4 IIM → ACR/EULAR moderate or major response All 24 patients discontinued immunosuppression. Aggregated 2024–25 reviews: Approximately 80–85% of refractory SLE patients in early-phase CAR-T trials achieve complete clinical response, most in drug-free remission at 6 months, many maintaining remission beyond 1 year. Subtle caveat highlighted by the authors: In lupus nephritis, persisting proteinuria may reflect chronic damage rather than ongoing activity, which can make complete clinical responses look less impressive than they truly are.\n4. Toxicity \u0026amp; Safety — The Distinctive Autoimmune Profile The toxicity pattern in autoimmune disease differs meaningfully from oncology, where tumour burden drives severity.\nMajor toxicities (Table 1 of the paper):\nCytokine Release Syndrome (CRS) Systemic inflammatory response — fever, hypotension, organ dysfunction Onset 1–7 days post-infusion In autoimmune cohorts: predominantly grade 0–1, occasional grade 2 Management: supportive care, tocilizumab, corticosteroids Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Headache, confusion, seizures 1–7 days post-infusion Rare in autoimmune cohorts; transient neurocognitive symptoms only Not observed in the CASTLE study Local Immune Effector Cell-Associated Toxicity Syndrome (LICATS) — newly described entity Occurred in 77% of 39 patients (SLE, SSc, IIM) 54 events total, distribution: Skin — 35% Kidneys — 22% Musculoskeletal — 19% Onset ~10 days post-infusion, during B-cell aplasia Resolves in ~11 days, usually without intensive treatment (brief steroids often suffice) Crucially: confined to organs previously involved by the underlying autoimmune disease No serology of flare, no histological evidence of active autoimmunity in limited biopsies Hypothesised to represent a local inflammatory \u0026ldquo;cleansing\u0026rdquo; during deep tissue B-cell depletion Recognising this is important to avoid inappropriately re-starting immunosuppression Immune Effector Cell (IEC)-Associated Enterocolitis Diarrhoea, abdominal pain, colitis Intra-epithelial lymphocytosis with villous blunting; CAR-T cells confirmed in lamina propria in one myeloma case FDA has issued updated black-box warnings in haematologic indications Management: supportive care, anti-inflammatories, immunosuppression (TNF inhibitors, integrin blockers) Other concerns Hypogammaglobulinaemia and infection risk — but early SLE data show preserved pre-existing vaccine titres (consistent with sparing of CD19-negative long-lived plasma cells) and capacity to boost on revaccination Class-wide regulatory warnings for secondary T-cell malignancies following BCMA- and CD19-CAR-T in oncology — drives the need for long-term surveillance in autoimmune recipients Practical bridging note: Gerber et al. (Lupus Sci Med 2025) showed that brief pulse corticosteroids during the immunosuppressive washout period can control severe lupus flares without compromising CAR-T expansion, B-cell depletion, or durable remission — a clinically useful tip.\n5. Beyond SLE — Expanding Indications Idiopathic Inflammatory Myopathies (IIM, including antisynthetase syndrome): CD19 CAR-T used as rescue after multiple failed B-cell-depleting antibodies Major gains in muscle strength, CK normalisation, resolution of lung involvement Subtle observation: Some patients showed later transient flares attributed to expansion of autoreactive CD8+ effector cells — possibly driven by low-grade LICATS. Highlights the need for T-cell monitoring. Systemic Sclerosis (SSc): A single infusion can stabilise/improve skin fibrosis, digital ischaemia, and pulmonary function — without ongoing immunosuppression Neurologic autoimmunity (not classic rheumatology but conceptually adjacent): BCMA- and CD19-CAR-T used in neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis → marked reductions in pathogenic autoantibodies, relapse rates, and disability scores. Supports the broader principle that B-lineage-directed cell therapy resets pathogenic humoral immunity across diverse antibody-mediated diseases. 6. Transient and Alternative Effector Platforms To circumvent the long-term risks of integrating vectors, manufacturing complexity, and lymphodepletion, several alternatives are under development:\nTransient RNA-based CAR-T RNA electroporation or mRNA vectors → CAR expression is finite In a Phase 1b/2a MG study: ex vivo RNA-engineered BCMA CAR-T allowed patients to remain on baseline immunosuppression, avoided lymphodepleting conditioning, enabled outpatient infusion, with minimal CRS/ICANS In a separate study, LNP-encapsulated CD19 CAR mRNA targeting CD8 T cells was given in repeated doses to 5 severe SLE patients — all generated CAR in vivo, achieved B-cell depletion, without high-grade CRS (in vivo CAR-T) Gamma-delta (γδ) T cells, CAR-NK, CAR-Treg Lower risks of severe CRS, ICANS, and GvHD CAR-Treg are particularly interesting — aim to enforce antigen-specific tolerance rather than just depleting B cells Allogeneic, gene-edited CAR products Healthy-donor-derived → standardised, off-the-shelf, rapid availability Finite persistence may reduce long-term risks while still delivering intense, time-limited B-lineage depletion Bispecific T Cell Engagers (TCEs) CD3 × B-cell antigen antibodies Blinatumomab (CD19 × CD3) in small RA cohorts: profound B-cell depletion, naïve-skewed reset, rapid clinical/imaging improvement, mostly low-grade infusion reactions CD19- and BCMA-directed TCE programmes ongoing in RA, SSc, dermatomyositis, primary Sjögren, and early SLE/LN 7. Mechanism: What \u0026ldquo;Immune Reset\u0026rdquo; Actually Means The authors emphasise that immune reset is more than transient B-cell depletion. Reported features include:\nDeep tissue (not just peripheral blood) B-cell depletion — validated histologically by Tur et al. (ARD 2025) Suppression of the type I interferon pathway B-cell reconstitution with a predominantly naïve phenotype Loss of pathogenic gene-expression signatures Durable remission even after B cells return — implying the qualitative nature of the new B-cell pool matters more than absolute count 8. Trial Design and Practical Guidance The Lupus Clinical Investigators Network (LCIN) consensus document (Caricchio et al., ACR Open Rheumatol 2025) provides discipline-specific guidance covering:\nPatient selection criteria Timing and conditions of leukapheresis Management of background immunosuppression and glucocorticoids during washout CRS and ICANS grading Infection prophylaxis Long-term follow-up frameworks The authors flag a paradoxical risk: too many parallel trials are diluting candidate patient pools and resources — calling for smarter trial designs that match patients to the most appropriate trial based on genetic, phenotypic, and disease characteristics.\nKey Takeaways for the Practising Rheumatologist CD19-directed CAR-T (especially CD19–4-1BB) is currently the most established platform, with consistent signals of deep, drug-free remission in refractory SLE (~80–85% complete response in early-phase trials), and promising responses in IIM and SSc. CD19 \u0026gt; CD20 mechanistically because it captures plasmablasts and tissue-resident B cells that anti-CD20 antibodies miss. This explains why even obinutuzumab, despite better depletion than rituximab, cannot fully replace the cellular approach. Toxicity in autoimmune disease is qualitatively different from oncology — mostly low-grade CRS, rare ICANS, and a new entity — LICATS — which is organ-specific, self-limited, and must not be confused with disease flare. LICATS should not trigger reflexive immunosuppression — recognise it, capture it systematically in trials, treat symptomatically. The Fra2 SSc model showing disease exacerbation with B-cell depletion is a sobering reminder that the SLE paradigm may not translate uniformly across autoimmune diseases — IIM patients may also flare via CD8+ expansion. Mechanism matters. Brief pulse steroids during washout can safely bridge severe flares without compromising CAR-T efficacy. Long-term safety remains uncertain — hypogammaglobulinaemia, infection risk, and the haematology-derived class-wide warning for secondary T-cell malignancies mandate disciplined long-term surveillance. The platform landscape is rapidly diversifying — allogeneic CARs, γδ-CARs, CAR-NK, CAR-Tregs, RNA CARs, in-vivo LNP-mRNA CARs, and bispecific T-cell engagers (CD19/CD3, BCMA/CD3) — each with potential trade-offs in persistence, manufacturing burden, and toxicity. Access and equity are the looming ethical challenges — cost, infrastructure, leukapheresis capacity, and specialised post-infusion monitoring are not trivial, and the field must plan for this proactively. CAR-T is not yet ready as routine therapy — it remains a highly selected, refractory-disease option requiring experienced centres, structured trials, and long-term registries. Final Take-Home Message Cellular therapy — particularly CD19-directed CAR-T — represents the first credible attempt at a true immunological reset in autoimmune rheumatic disease, replacing the chronic-suppression paradigm with a one-and-done intervention aimed at qualitatively rebuilding the B-cell compartment. The early efficacy signals in refractory SLE, IIM, and SSc are extraordinary; the toxicity profile in autoimmune cohorts is so far more favourable than in oncology; and the platform diversity (allogeneic, RNA, TCE, NK) suggests this is the beginning, not the endpoint.\nFor rheumatologists, the responsibilities going forward are clear: rigorous patient selection, long-term surveillance, systematic capture of new toxicities like LICATS, avoidance of duplicative trial competition, and advocacy for equitable access — so that the most transformative therapy our field has seen in a generation does not become available to only a privileged few.\nOriginal article Koumpouras F, Caricchio R. Cellular therapies for rheumatic disease. Curr Opin Rheumatol (2026).\ndoi:10.1097/BOR.0000000000001159 ","permalink":"https://rheumatologydigest.org/posts/cellular-therapies-for-rheumatic-disease/","summary":"CD19 CAR-T cellular therapy delivers drug-free remission in 80–85% of refractory SLE patients in early-phase trials, with similar signals in IIM and SSc — the first credible attempt at true immunological reset in autoimmune rheumatic disease.","title":"Cellular therapies for rheumatic disease"},{"content":"Rheumatology Digest now has a permanent web home.\nFor years, this content has lived on WhatsApp — short clinical write-ups, infographics, and case discussions shared with colleagues across India. That format will continue, but everything will also be archived here, searchable, tagged, and easy to revisit.\nWhat you\u0026rsquo;ll find here Daily digest entries — concise clinical write-ups on rheumatology topics Cases — case-based learning with discussion of reasoning and management Quizzes — quick self-assessment on common and uncommon scenarios Modules — structured, multi-part learning on focused topics A note on the build This is the first post on the new site, published while the platform is still being set up. Expect rapid changes to layout, navigation, and styling over the coming weeks as the design settles in.\n— Dr. Sree Hari Reddy MD\n","permalink":"https://rheumatologydigest.org/posts/welcome-to-rheumatology-digest/","summary":"A new permanent home for Rheumatology Digest — daily clinical write-ups, cases, quizzes, and learning modules.","title":"Welcome to Rheumatology Digest"}]